Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Second-line phase II study of tremelimumab monotherapy in unresectable malignant mesothelioma
2012-002762-12Phase 2Completed
- Sponsor
- Azienda Ospedaliera Universitaria Senese
- Start
- Aug 2012
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tremelimumab in mesothelioma, sponsored by Azienda Ospedaliera Universitaria Senese. Primary endpoint: Objective response rate (CR + PR). Started Aug 2012; status: completed.
02
Drugs
tremelimumab
03
Conditions
mesothelioma
Beyond the preview
Go deeper on 2012-002762-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002762-12.